ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma
DRUG: brentuximab vedotin|DRUG: doxorubicin|DRUG: prednisone|DRUG: vincristine|DRUG: cyclophosphamide
Progression-free Survival Per Independent Review Facility (IRF), The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first., Up to 60 months
Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL), The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first., Up to 60 months|Complete Remission (CR) Rate Per IRF at End of Treatment (EOT), The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma., Up to 8.34 months|Overall Survival (OS), The time from randomization to death due to any cause., Up to 90 months|Objective Response Rate (ORR) Per IRF at End of Treatment, The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma., Up to 8.34 months|Incidence of Adverse Events (AEs), Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment., Up to 8.28 months|Incidence of Laboratory Abnormalities, Number of participants who experienced a Grade 3 or higher laboratory toxicity., Up to 8.28 months
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.